| Website | neuraltus.com |
| Category | BioTech |
| Phone | (650) 424-1600 |
| npinfo@neuraltus.com | |
| Employees |
| TOTAL | $26.6M |
| FUNDING TOTAL | $26.6M |
| Series A, 3/09 Latterell Venture Partners Adams Street Partners VantagePoint Capital Partners | $17M |
| Series B, 1/12 Latterell Venture Partners Adams Street Partners VantagePoint Capital Partners | $9.6M |
Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease), Parkinson’s disease and dyskinesias associated with the treatment of Parkinson’s disease, Alzheimer’s disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry’s disease and Gaucher’s disease. Each of Neuraltus’ clinical-stage programs is advancing novel drug molecules that represent new, first-in-class approaches to treating the Company’s target disease indications.
Neuraltus began operations in 2009 based on a broadly enabling technology portfolio and intellectual property assembled by the company founders, Ari Azhir, PhD, Neuraltus’ Chief Operating Officer; Michael McGrath, MD, PhD, Professor of Laboratory Medicine at the University of California, San Francisco; and Edgar Engleman, MD, Professor of Medicine and Pathology at Stanford University School of Medicine. In March 2009 Neuraltus closed a $17M Series A financing with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners
